Contract Pharma14m
Biologics R&D: Derisking Scale-up and Tox Supply
As a biologics CDMO focused on developing and manufacturing recombinant protein products using mammalian cell culture ...
Contract Pharma20m
FDA Grants Priority Review to Boehringer Ingelheim’s NDA for Zongertinib
The U.S. Food and Drug Administration (FDA) has granted Priority Review to Boehringer Ingelheim’s new drug application for zongertinib (BI 1810631) for the treatment of adult patients with ...
Boehringer’s zongertinib receives Priority Review from U.S. FDA for the treatment of HER2 (ERBB2)-mutant advanced non-small cell lung cancer
Ridgefield, Conn., U.S., and Ingelheim, GermanyZongertinib would be the first orally administered, targeted therapy for previously treated ...
GEN6d
ExpressionEdits Partners with Boehringer to Enhance Gene Therapies with AI-Based Intron Design
Boehringer will leverage ExpressionEdits' Genetic Syntax Engine which generates optimized introns to increase protein expression.
Hosted on MSN8d
Boehringer seeks approval of lung disease drug after second Phase III success
Boehringer Ingelheim’s lung disease drug nerandomilast has been successful in a Phase III study paving the way for the ...
ENDPOINTS NEWS25d
Boehringer merges can­cer vac­cine and on­colyt­ic virus teams; Dan­tari sells off as­sets
Plus, news about Madrona and Ab­dera: Boehringer In­gel­heim com­bines two can­cer units: The drug­mak­er is merg­ing its can­cer vac­cine unit AMAL Ther­a­peu­tics … ...